Volume 28, Supplement—December 2022
SUPPLEMENT ISSUE
Clinical
Effectiveness of Whole-Virus COVID-19 Vaccine among Healthcare Personnel, Lima, Peru
Table 2
Vaccination status† |
COVID-19 cases |
Non—COVID-19 cases |
Vaccine effectiveness, % (95% CI)‡ |
|||||
---|---|---|---|---|---|---|---|---|
Vaccinated |
Unvaccinated |
Vaccinated |
Unvaccinated |
Unadjusted |
Adjusted |
|||
Received >1 vaccine dose | 10 | 9 | 138 | 6 | 95 (84–99) | 97 (88–99) | ||
Fully vaccinated | 5 | 9 | 36 | 6 | 91 (63–98) | 95 (70–99) | ||
Partially vaccinated | 5 | 9 | 25 | 6 | 87 (45–97) | 100 (88–100) |
*Totals exclude persons with reactive SARS-CoV-2 serology (n = 106) and persons with positive COVID-19 test before February 9, 2021 (n = 17). †Persons who tested positive before vaccination date or before the 2-week period after vaccination were considered unvaccinated for the model. We defined full vaccination as the period starting 14 d after receipt of the second dose and partial vaccination as the period starting 14 d after receipt of the first dose. Participants not meeting these criteria were considered unvaccinated. The partial vaccination model only included persons who received 1 dose of the vaccine during the study period. ‡Adjusted for age, sex, exposure to COVID-19 patients, work in the intensive care unit, work in the emergency department, body-mass index, and time of follow-up in days.